Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244546 | 0.89 | L3MBTL1 (0.42) | L3MBTL1LPAR1MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL10282712 | 0.85 | SLC6A4 (0.43) | L3MBTL1MTNR1AMTNR1BHSD17B10HTT | |
| SCHEMBL10244221 | 0.80 | ALDH1A1 (0.38) | L3MBTL1HSD17B10HTTMEN1KMT2A | |
| SCHEMBL10243117 | 0.77 | L3MBTL1 (0.41) | L3MBTL1MTNR1AMTNR1BHSD17B10HTT | |
| SCHEMBL10282559 | 0.77 | HPGD (0.42) | L3MBTL1MTNR1AMTNR1BHSD17B10HTT | |
| SCHEMBL334589 | 0.76 | MC4R (0.38) | L3MBTL1HTTMEN1KMT2APOLB | |
| SCHEMBL334590 | 0.76 | MC4R (0.38) | L3MBTL1HTTMEN1KMT2APOLB | |
| SCHEMBL10244325 | 0.74 | MTNR1A (0.38) | L3MBTL1LPAR1MTNR1AMTNR1BHTT | |
| SCHEMBL10282710 | 0.72 | APP (0.43) | L3MBTL1HTTHPGDMEN1KMT2A | |
| SCHEMBL10243705 | 0.72 | HCRTR1 (0.43) | L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | L3MBTL1 2853/4885LPAR1 775/4885MTNR1A 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.